AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex
PLOS One · 30.09.2026 · 21 (9) · e0359269
DOI: 10.1371/journal.pone.0359269 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 30.09.2026. Verfasst von Noelle Callizot und 9 weiteren Autor:innen. Beteiligte Einrichtung: Neuro-Sys, Chemin Départemental, Gardanne, France. Hauptthemen laut MEDLINE: Lysosomes, Saposins, Neuroprotective Agents, Parkinson Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzprotect, Michael J. Fox Foundation.
Abstract (Originalsprache)
The pathohistological hallmarks of Parkinson’s disease are aggregated alpha-synuclein and other aggregation-prone proteins (Lewy bodies). Recent studies show mechanistic as well as genetic connections between lysosomal dysfunction and Parkinson’s disease pathology. A direct link between lysosomal function and Parkinson’s disease might be the degradation of alpha-synuclein within the lysosomal system. Progranulin is necessary for maintaining lysosomal function, facilitating the activity of several lysosomal enzymes. Progranulin’s exit from the endoplasmic reticulum and its lysosomal availability depend on an interaction with Prosaposin. AZP2006 (INN: Ezeprogind) is a small lysosomotropic neuroprotective molecule currently in clinical development in Progressive Supranuclear Palsy patients. Its neuroprotective effects involve the Progranulin/Prosaposin complex. In this study, we investigated the neuroprotective effects of AZP2006 in several Parkinson’s-like models ( vitro and vivo ). We showed that AZP2006 was able to counteract a mitochondrial injury as well as the toxicity of alpha-synuclein preformed fibril spreading. We proved that Progranulin was involved in AZP2006’s neuroprotective action, restoring lysosomal homeostasis and ultimately supporting the health of dopaminergic neurons. In light of this evidence, strategies with the aim of improving Progranulin and Prosaposin levels and activity offer a promising therapeutic approach in the context of proteinopathies such as Parkinson’s disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Neuro-Sys, Chemin Départemental, Gardanne, France.
- Alzprotect, Parc Eurasanté, Loos, France.
ORCID-Profile: Georgia Culley, Philippe Verwaerde
Förderung
- Alzprotect
- Michael J. Fox Foundation
Zitieren
APA
Callizot, N., Culley, G., Flower, G., Rouvière, L., De Conto, V., Wojcinski, A., Botto, C., Estrella, C., Henriques, A., & Verwaerde, P. (2026). AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex. PLOS One, 21(9), e0359269. https://doi.org/10.1371/journal.pone.0359269
Vancouver
Callizot N, Culley G, Flower G, Rouvière L, De Conto V, Wojcinski A, et al. AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex. PLOS One. 2026;21(9):e0359269. doi:10.1371/journal.pone.0359269
BibTeX
@article{Callizot2026,
author = {Callizot, Noelle and Culley, Georgia and Flower, Grace and Rouvière, Laura and De Conto, Véronique and Wojcinski, Alexandre and Botto, Catherine and Estrella, Cecilia and Henriques, Alexandre and Verwaerde, Philippe},
title = {AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {9},
pages = {e0359269},
doi = {10.1371/journal.pone.0359269}
}
EUVIMED